Brief: Incannex Healthcare Receives IRB Approval For Reposa Phase 2/3 Clinical Trial Protocol
17/01/2024 11:13
Jan 17 (Reuters) - Incannex Healthcare Inc IQI0y.F :
* INCANNEX HEALTHCARE:RECEIVES IRB APPROVAL FOR REPOSA PHASE
2/3
CLINICAL TRIAL PROTOCOL TO ASSESS IHL-42X DRUG IN PATIENTS WITH
OBSTRUCTIVE SLEEP APNEA
Further company coverage: IQI0y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Incannex Healthcare
See all newsIncannex Healthcare Inc reports results for the quarter ended June 30 - Earnings Summary
Incannex Healthcare Inc expected to post a loss of 75 cents a share - Earnings Preview
Brief: Incannex Receives Additional A$5.1 Million Research And Development Tax Incentive Refund
Brief: Incannex Healthcare Commences DReAMzz Clinical Study Of IHL-42X For Obstructive Sleep Apnea
Brief: Incannex Reactivates Share Repurchase Program, Underscoring Confidence In Valuation And Strategic Position